IsoTis Establishes Wound Management Subsidiary

The new company is called EpiSource and its portfolio will include EpiDex, Allox, and AcuDress, products that are in various stages of development and approval.

"With EpiDex reimbursed, AcuDress on the market, and Allox meeting its critical milestones, the commercial value of the pipeline of the new subsidiary EpiSource is materializing, giving it an excellent position to seek partners in Switzerland to further advance its business potential,” said Jacques Essinger, CEO of IsoTis OrthoBiologics.

IsoTis OrthobBiologics was created in the fourth quarter of 2003 through the merger of GenSci OrthoBiologics, a US-based orthobiology company, and IsoTis SA, a Swiss-Dutch biomedical company. The field of orthobiologics combines advances in biotechnology, materials sciences, and tissue biology to promote and enhance the body's natural ability to regenerate and repair musculoskeletal tissue. IsoTis is developing a broad presence in both "natural” demineralized bone matrix (DBM) products and "synthetic” bone graft substitutes, carrier technologies, and biologically based growth factors. IsoTis states that orthobiologics is the fastest-growing segment of the U.S.$16 billion orthopedics market.





Related Links:
IsoTis